A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age

Recruiting

Phase 3

GSK & MerckA Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age

Sponsor:

GlaxoSmithKline

Code:

NCT06855160

Conditions

Chickenpox

Eligibility Criteria

Sex: All

Age: 1

Healthy Volunteers: Accepted

Interventions

Candidate varicella vaccine

Marketed varicella vaccine

MMR vaccine

Hepatitis A vaccine

PCV (pneumococcal conjugate vaccine) 13

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-11. This information was provided to ClinicalTrials.gov by GlaxoSmithKline on 2025-06-17.